CD4(+) T cells stratification unveils a dynamic pathogen landscape in severe pneumonia: a targeted next-generation sequencing-based cohort study

CD4(+) T 细胞分层揭示重症肺炎中病原体动态变化:一项基于靶向二代测序的队列研究

阅读:1

Abstract

BACKGROUND: The host's immune status is a critical determinant of the pathogen profile in pulmonary infections, but quantitative indicators to delineate this dynamic association are lacking. This study aimed to use CD4(+) T cells count as an objective parameter to systematically characterize the evolution of the pathogen profile in bronchoalveolar lavage fluid-targeted next-generation sequencing (BALF-tNGS) from patients with severe pneumonia. METHODS: We retrospectively analyzed 286 adult patients who underwent BALF-tNGS for severe pneumonia. Patients were stratified into four strata based on CD4(+) T cells count: severe immunosuppression, moderate immunosuppression, low-normal immunity, and immunocompetent. Cochran-Armitage trend test, cluster analysis, and Kruskal-Wallis test were used to analyze the associations between CD4(+) T cells strata and pathogen detection rates/co-infection complexity. RESULTS: The detection rates of Pneumocystis jirovecii (PJP) and Cytomegalovirus (CMV) showed a highly significant increasing trend with decreasing CD4(+) T cells strata (p < 0.05). CD4(+) T cells count < 100 cells/μL was the most significant risk factor for PJP infection (detection rate 39.6%). Meanwhile, as the CD4(+) T cells count decreased, the number of pathogen species detected in the patient's BALF significantly increased, with a statistically significant difference between groups (p < 0.05). The median number in the severe immunosuppression stratum was significantly higher than that in the immunocompetent stratum. CONCLUSION: The CD4(+) T cells count quantitatively defines the pathogen ecology in pulmonary infections. A CD4(+) T cells count < 100 cells/μL represents a critical threshold for opportunistic infections and complex co-infections. These findings support the integration of CD4(+) T cells counting into the initial assessment framework for severe pneumonia to guide precise empirical therapy and diagnostic strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。